Skip to Content

Tofacitinib use while Breastfeeding

Drugs containing Tofacitinib: Xeljanz, Xeljanz XR

Medically reviewed by Drugs.com. Last updated on Oct 21, 2020.

Tofacitinib Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of tofacitinib during breastfeeding. Until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant. The manufacturer and an expert panel recommend that breastfeeding be discontinued during tofacitinib therapy and for 18 hours after the last dose of Xeljanz or 36 hours after the last dose of Xeljanz XR.[1]

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

(Rheumatoid Arthritis) Adalimumab, Certolizumab Pegol, Etanercept, Infliximab, Tocilizumab

References

1.
Mahadevan U, Robinson C, Bernasko N, et al. Inflammatory bowel disease in pregnancy clinical care pathway: A report from the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019;156:1508–24. [PubMed: 30658060]

Substance Identification

Substance Name

Tofacitinib

CAS Registry Number

477600-75-2

Drug Class

Breast Feeding

Lactation

Antirheumatic Agents

Enzyme Inhibitors

Janus Kinase Inhibitors

JAK Inhibitors

Signal Transduction Inhibitors

Protein Kinase Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.